In vitro experiments have shown that avelumab triggered ADCC against TNBC cells expressing detectable levels of PD-L1, with a significant increase in tumor cell lysis independently of the blockade of the PD-1/PD-L1 axis; besides its use with immunomodulators such as interleukin (IL) 2 or IL-15 may improve the therapeutic efficacy of avelumab itself [82]. This evidence concerns the gene IL15 and neoplasm.